Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Medicus Pharma Ltd (MDCX.VN)

Medicus Pharma Ltd (MDCX.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 67,839
  • Shares Outstanding, K 11,923
  • Annual Sales, $ 0 K
  • Annual Income, $ -11,156 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 13.64
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.88
  • Most Recent Earnings $-0.31 on 11/25/24
  • Next Earnings Date 04/29/25
  • Annual Dividend & Yield (Fwd) N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING TSX Drug Manufacturers - Major

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.45
  • Number of Estimates 2
  • High Estimate -0.42
  • Low Estimate -0.48
  • Prior Year -0.25
  • Growth Rate Est. (year over year) -80.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.840 +48.18%
on 02/04/25
5.910 -3.72%
on 02/21/25
+1.440 (+33.88%)
since 01/21/25
3-Month
2.620 +117.18%
on 11/25/24
5.910 -3.72%
on 02/21/25
+3.140 (+123.14%)
since 11/21/24
52-Week
1.480 +284.46%
on 07/03/24
7.000 -18.71%
on 10/28/24
+3.090 (+118.85%)
since 02/21/24

Most Recent Stories

More News
Medicus Pharma Ltd. Announces Pricing of $4.2 Million Regulation A Offering

Philadelphia, Pennsylvania--(Newsfile Corp. - March 6, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) (the "Company") today announced the pricing of its Tier II Regulation A offering of 1,490,000 units, on...

MDCX : 1.3600 (+11.48%)
MDCX.VN : 5.690 (-0.18%)
Medicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

The Interim Analysis Showed Complete Clinical Clearance of More than Sixty (60%) PercentPhiladelphia, Pennsylvania--(Newsfile Corp. - March 6, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the...

MDCX : 1.3600 (+11.48%)
MDCX.VN : 5.690 (-0.18%)
Medicus Pharma Ltd Announces Submission of Phase 2 Clinical Design (SKNJCT-004) to United Arab Emirates (UAE) Department of Health (DOH) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

The Clinical Study is Expected to Randomize 36 Participants in Cleveland Clinic Abu Dhabi (CCAD) and Three Other Clinical Sites in UAEPhiladelphia, Pennsylvania--(Newsfile Corp. - February 27, 2025) -...

MDCX : 1.3600 (+11.48%)
MDCX.VN : 5.690 (-0.18%)
Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)

The Company Is on Track to Complete the Interim Data Analysis Before the End of Q1 2025 and to Submit the Findings to the U.S. Food and Drug Administration (FDA)Philadelphia, Pennsylvania--(Newsfile Corp....

MDCX : 1.3600 (+11.48%)
MDCX.VN : 5.690 (-0.18%)
Medicus Pharma Ltd. Enters into Standby Equity Purchase Agreement and Announces Intention to Voluntarily Delist from the TSX Venture Exchange (TSXV)

Medicus Pharma Ltd.'s shares will remain listed on the NASDAQ Capital MarketToronto, Ontario and Philadelphia, Pennsylvania--(Newsfile Corp. - February 11, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus"...

MDCX : 1.3600 (+11.48%)
MDCX.VN : 5.690 (-0.18%)
Medicus Pharma Ltd. Announces Minor Use (MUMS) Designation from the FDA for Doxorubicin-Containing Microneedle Array (D-MNA) Patch

Company to Submit Product Development Plan to Treat External Squamous Cell Carcinoma (SCC) in HorsesToronto, Ontario and Philadelphia, Pennsylvania--(Newsfile Corp. - December 12, 2024) - Medicus Pharma...

MDCX : 1.3600 (+11.48%)
MDCX.VN : 5.690 (-0.18%)
Medicus Pharma Ltd. Announces Collaboration Agreement to Expand Phase 2 Clinical Study in Asia Pacific Region

Provides Update on SKNJCT-003 Phase 2 Clinical Study for Treatment of Nodular Basal Cell Carcinoma (BCC) Currently Underway in United StatesToronto, Ontario and Philadelphia, Pennsylvania--(Newsfile Corp....

MDCX : 1.3600 (+11.48%)
MDCX.VN : 5.690 (-0.18%)
Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer

Promotes Edward Brennan, MD, FACS to Chief Scientific Officer & Head of R&D ProgramToronto, Ontario and Philadelphia, Pennsylvania--(Newsfile Corp. - November 18, 2024) - Medicus Pharma Ltd (NASDAQ: MDCX)...

MDCX : 1.3600 (+11.48%)
MDCX.VN : 5.690 (-0.18%)
Medicus Pharma Ltd. Announces Closing of US$4.0M Initial Public Offering in the United States

Toronto, Ontario and Philadelphia, Pennsylvania--(Newsfile Corp. - November 15, 2024) - Medicus Pharma Ltd (NASDAQ: MDCX) (TSXV: MDCX) (the "Company") today announced the closing of its previously announced...

MDCX : 1.3600 (+11.48%)
MDCX.VN : 5.690 (-0.18%)
Medicus Pharma Ltd. Announces Pricing of US$4.0M Initial Public Offering in the United States

Toronto, Ontario and Philadelphia, Pennsylvania--(Newsfile Corp. - November 13, 2024) - Medicus Pharma Ltd (NASDAQ: MDCX) (TSXV: MDCX) (the "Company") today announced the pricing of its initial public...

MDCX.VN : 5.690 (-0.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.

See More

Key Turning Points

3rd Resistance Point 6.057
2nd Resistance Point 5.983
1st Resistance Point 5.837
Last Price 5.690
1st Support Level 5.617
2nd Support Level 5.543
3rd Support Level 5.397

See More

52-Week High 7.000
Last Price 5.690
Fibonacci 61.8% 4.891
Fibonacci 50% 4.240
Fibonacci 38.2% 3.589
52-Week Low 1.480

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar